Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.

Martin Forster Irene Brana Antonio L Pousa Bernard Doger Patricia Roxburgh Pawan Bajaj Julio Antonio Peguero Matthew G Krebs Enric Carcereny Grisma Patel Christian Mueller Chrystelle Brignone Frederic Triebel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Efti plus pembrolizumab was safe and showed encouraging antitumor activity and pharmacodynamic effects in patients with second-line head and neck squamous cell carcinoma (HNSCC), thus supporting further evaluation of this combination in earlier treatment lines.

Keyphrases

advanced non small cell lung cancer
protein protein
small molecule